Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 19.5 8.15% 1.47
APLS closed up 8.15 percent on Wednesday, January 17, 2018, on 19 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A N/A Down
See historical APLS trend table...

Date Alert Name Type % Chg
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 17 Stochastic Reached Oversold Weakness 0.00%
Jan 17 Multiple of Ten Bearish Other 0.00%
Jan 17 Outside Day Range Expansion 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 1,2,3 Pullback Bullish Bullish Swing Setup 8.15%
Jan 16 Wide Bands Range Expansion 8.15%
Jan 16 Down 3 Days in a Row Weakness 8.15%
Jan 16 Down 4 Days in a Row Weakness 8.15%

Older signals for APLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Is APLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.49
52 Week Low 12.45
Average Volume 209,999
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 19.598
10-Day Moving Average 21.246
Average True Range 1.7787
ADX 33.49
+DI 27.02
-DI 20.84
Chandelier Exit (Long, 3 ATRs ) 20.1539
Chandelier Exit (Short, 3 ATRs ) 17.8361
Upper Bollinger Band 25.4652
Lower Bollinger Band 13.7308
Percent B (%b) 0.49
BandWidth 59.875497
MACD Line 1.2191
MACD Signal Line 1.6913
MACD Histogram -0.4723
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.04
Resistance 3 (R3) 22.86 21.51 22.45
Resistance 2 (R2) 21.51 20.61 21.60 22.25
Resistance 1 (R1) 20.50 20.05 21.01 20.68 22.06
Pivot Point 19.15 19.15 19.40 19.24 19.15
Support 1 (S1) 18.14 18.25 18.65 18.32 16.94
Support 2 (S2) 16.79 17.69 16.88 16.75
Support 3 (S3) 15.78 16.79 16.55
Support 4 (S4) 15.96